JOP20190183B1 - معدِلات مستقبلات الاستروجين - Google Patents

معدِلات مستقبلات الاستروجين

Info

Publication number
JOP20190183B1
JOP20190183B1 JOP/2019/0183A JOP20190183A JOP20190183B1 JO P20190183 B1 JOP20190183 B1 JO P20190183B1 JO P20190183 A JOP20190183 A JO P20190183A JO P20190183 B1 JOP20190183 B1 JO P20190183B1
Authority
JO
Jordan
Prior art keywords
estrogen receptor
receptor modulators
formula
disorders
processes
Prior art date
Application number
JOP/2019/0183A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
James Stewart Scott
Thomas Andrew MOSS
Johannes Wilhelmus Maria Nissink
Samantha Jayne HUGHES
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20190183A1 publication Critical patent/JOP20190183A1/ar
Application granted granted Critical
Publication of JOP20190183B1 publication Critical patent/JOP20190183B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة (I) صورة (I) وبأملاح مقبولة صيدلانياً منها، بعمليات ومركبات وسيطة تستخدم لتحضيرها، بتركيبات صيدلانية تحتوي عليها وباستخدامها في معالجة اضطرابات التكاثر الخلوي. الصيغة I
JOP/2019/0183A 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين JOP20190183B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JOP20190183A1 JOP20190183A1 (ar) 2019-07-28
JOP20190183B1 true JOP20190183B1 (ar) 2022-09-15

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0183A JOP20190183B1 (ar) 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين

Country Status (35)

Country Link
US (3) US10221173B2 (ar)
EP (2) EP3494116B1 (ar)
JP (1) JP6951451B2 (ar)
KR (1) KR102246668B1 (ar)
CN (1) CN110214140B (ar)
AU (1) AU2018211495B2 (ar)
CL (1) CL2019001991A1 (ar)
CO (1) CO2019008941A2 (ar)
CR (1) CR20190379A (ar)
CY (1) CY1122731T1 (ar)
DK (1) DK3494116T3 (ar)
DO (1) DOP2019000183A (ar)
EC (1) ECSP19062381A (ar)
ES (2) ES2931320T3 (ar)
HU (1) HUE047761T2 (ar)
IL (1) IL268263B (ar)
JO (1) JOP20190183B1 (ar)
LT (1) LT3494116T (ar)
MA (1) MA52555A (ar)
MX (1) MX2019008438A (ar)
MY (1) MY196317A (ar)
NI (1) NI201900080A (ar)
PE (1) PE20191500A1 (ar)
PH (1) PH12019501724A1 (ar)
PL (1) PL3494116T3 (ar)
PT (1) PT3494116T (ar)
RS (1) RS59770B1 (ar)
SG (1) SG11201906767XA (ar)
SI (1) SI3494116T1 (ar)
SM (1) SMT202000010T1 (ar)
TN (1) TN2020000009A1 (ar)
TW (1) TWI794205B (ar)
UA (1) UA125043C2 (ar)
WO (1) WO2018138303A1 (ar)
ZA (1) ZA201904696B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5314242B2 (ja) * 2004-04-27 2013-10-16 中外製薬株式会社 プラズマ細胞の増殖方法
EP1863810A4 (en) 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
EP3312184A4 (en) 2015-06-16 2019-02-27 Jiangsu Hengrui Medicine Co., Ltd. PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
EP3378861B1 (en) 2015-11-12 2021-08-04 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
WO2017107754A1 (zh) 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) * 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
JP6793836B2 (ja) 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
AR110782A1 (es) 2017-01-30 2019-05-02 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa

Also Published As

Publication number Publication date
PE20191500A1 (es) 2019-10-22
TN2020000009A1 (en) 2021-10-04
US10221173B2 (en) 2019-03-05
ECSP19062381A (es) 2019-09-30
HUE047761T2 (hu) 2020-05-28
WO2018138303A1 (en) 2018-08-02
RS59770B1 (sr) 2020-02-28
EP3494116B1 (en) 2019-10-23
MA52555A (fr) 2021-03-17
ES2766249T3 (es) 2020-06-12
US10590132B2 (en) 2020-03-17
CL2019001991A1 (es) 2019-10-11
CO2019008941A2 (es) 2019-08-30
UA125043C2 (uk) 2021-12-29
DOP2019000183A (es) 2019-07-31
CN110214140B (zh) 2022-08-30
KR102246668B1 (ko) 2021-04-29
SG11201906767XA (en) 2019-08-27
BR112019015389A2 (pt) 2020-03-10
JP2020505354A (ja) 2020-02-20
AU2018211495A1 (en) 2019-09-12
SMT202000010T1 (it) 2020-03-13
KR20190112767A (ko) 2019-10-07
PL3494116T3 (pl) 2020-04-30
LT3494116T (lt) 2020-01-10
US20200239468A1 (en) 2020-07-30
AU2018211495B2 (en) 2020-05-21
TWI794205B (zh) 2023-03-01
SI3494116T1 (sl) 2020-02-28
EP3494116A1 (en) 2019-06-12
MY196317A (en) 2023-03-24
EP3689873B1 (en) 2022-09-14
NI201900080A (es) 2020-03-18
IL268263B (en) 2021-10-31
MX2019008438A (es) 2019-10-30
US20180282325A1 (en) 2018-10-04
PH12019501724A1 (en) 2020-06-01
JOP20190183A1 (ar) 2019-07-28
TW201840558A (zh) 2018-11-16
ZA201904696B (en) 2020-05-27
US20190233413A1 (en) 2019-08-01
IL268263A (en) 2019-09-26
ES2931320T3 (es) 2022-12-28
CY1122731T1 (el) 2021-05-05
JP6951451B2 (ja) 2021-10-20
US11046689B2 (en) 2021-06-29
CA3050337A1 (en) 2018-08-02
EP3689873A1 (en) 2020-08-05
CN110214140A (zh) 2019-09-06
DK3494116T3 (da) 2020-01-27
CR20190379A (es) 2019-10-21
PT3494116T (pt) 2020-01-28

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
NZ737399A (en) Ccr2 modulators
PH12021550048A1 (en) Selective estrogen receptor degraders.
TW201613864A (en) Novel compounds
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201992679A1 (ru) N-замещенные индольные производные
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX377481B (es) Derivados de serina como agonistas del receptor de grelina.
EA201991734A1 (ru) Модуляторы рецептора эстрогена
EA202092600A1 (ru) Тетрациклические гетероарильные соединения